MONALEESA三期研究内在亚型与ribociclib疗效的相关性生物标志物分析
该研究对MONALEESA-2、-3、-7三项III期试验中1160例HR+/HER2-晚期乳腺癌肿瘤样本进行回顾性PAM50分型分析,评估内在亚型与无进展生存期(PFS)的关系。结果显示各亚型与PFS显著相关(P<.001),除基底样亚型外,所有亚型均从ribociclib(RIB)治疗中显著获益。
要点
- LumB、HER2E和基底样亚型疾病进展风险分别为LumA的1.44、2.31和3.96倍。
- 除基底样亚型外,所有亚型均显示RIB显著PFS获益。
- 基底样亚型(n=30)未从RIB获益(HR=1.15,P=.77)。
核心结论
- 在HR+/HER2-晚期乳腺癌中,除基底样亚型外,各内在亚型均一致显示RIB的PFS获益。
研究设计与样本
- 回顾性探索性分析,基于PAM50对MONALEESA-2、-3、-7三项III期试验的肿瘤样本进行分型。
- 共纳入1160例肿瘤样本,其中RIB组672例,安慰剂组488例。
- 采用多变量Cox比例风险模型评估亚型与PFS的关系,并调整年龄、既往化疗、体能状态等因素。
主要发现
- 亚型分布:LumA 46.7%,LumB 24.0%,正常样14.0%,HER2E 12.7%,基底样2.6%。
- 两治疗组中亚型与PFS的关联均具有统计学显著性(P<.001)。
- 与LumA相比,LumB、HER2E和基底样亚型的疾病进展风险分别高1.44、2.31和3.96倍。
- RIB组中各亚型PFS获益:HER2E(HR=0.39,P<.0001)、LumB(HR=0.52,P<.0001)、LumA(HR=0.63,P=.0007)、正常样(HR=0.47,P=.0005)。
- 基底样亚型(n=30)未显示RIB获益(HR=1.15,P=.77)。
临床怎么用
- PAM50内在亚型可帮助识别RIB治疗获益人群,除基底样亚型外均可考虑RIB联合内分泌治疗。
- 基底样亚型患者可能无法从RIB治疗中获益,需考虑其他治疗策略。
局限性
- 回顾性探索性分析,样本量有限,尤其基底样亚型仅30例。
- 结果需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The prognostic and predictive value of intrinsic subtypes in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with endocrine therapy and ribociclib (RIB) is currently unknown. We evaluated the association of intrinsic subtypes with progression-free survival (PFS) in the MONALEESA trials. METHODS: A retrospective and exploratory PAM50-based analysis of tumor samples from the phase III MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials was undertaken. The prognostic relationship of PAM50-based subtypes with PFS and risk of disease progression by subtype and treatment were evaluated using a multivariable Cox proportional hazards model, adjusting for age, prior chemotherapy, performance status, visceral disease, bone-only metastases, histological grade, number of metastatic sites, prior endocrine therapy, and de novo metastatic disease. RESULTS: Overall, 1,160 tumors from the RIB (n = 672) and placebo (n = 488) cohorts were robustly profiled. Subtype distribution was luminal A (LumA), 46.7%; luminal B (LumB), 24.0%; normal-like, 14.0%; HER2-enriched (HER2E), 12.7%; and basal-like, 2.6% and was generally consistent across treatment arms and trials. The associations between subtypes and PFS were statistically significant in both arms (P < .001). The risks of disease progression for LumB, HER2E, and basal-like subtypes were 1.44, 2.31, and 3.96 times higher compared with those for LumA, respectively. All subtypes except basal-like demonstrated significant PFS benefit with RIB. HER2E (hazard ratio [HR], 0.39; P < .0001), LumB (HR, 0.52; P < .0001), LumA (HR, 0.63; P = .0007), and normal-like (HR, 0.47; P = .0005) subtypes derived benefit from RIB. Patients with basal-like subtype (n = 30) did not derive benefit from RIB (HR, 1.15; P = .77). CONCLUSION: In this retrospective exploratory analysis of hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer, each intrinsic subtype exhibited a consistent PFS benefit with RIB, except for basal-like.
引用
- Prat A, Chaudhury A, Solovieff N, et al. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. J Clin Oncol. 2021. PMID: 33769862. doi:10.1200/JCO.20.02977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。